Shares will cease trading and be removed from Nasdaq; investors should expect final settlement from the acquisition. No further public filings or trading activity will occur.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK AT ENTRY AT T+1- T+0 · Apr 23 $21.53entry
- T+1 · 7mo ago 0.00%α −0.78% · $21.53
- T+5 · due 7mo ago Pending
- T+20 · due 6mo ago Pending
- T+60 · due 4mo ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Nasdaq has filed Form 25 to delist Day One Biopharmaceuticals (DAWN) common stock, effective immediately, following the company's acquisition by Servier Pharmaceuticals. This is a procedural step confirming the completion of the take-private transaction.
Key Facts
- Form 25-NSE filed by Nasdaq to delist DAWN common stock
- Effective date of delisting is 2026-04-23
- Follows the previously announced acquisition of Day One by Servier Pharmaceuticals
- Merger closed after Servier secured 85.34% of shares via tender offer
- DAWN is no longer a publicly traded company
Financial Impact
Entire company acquired for $2.5 billion in all-cash transaction
Risk Factors
- None for public shareholders, transaction is complete and fully settled
- Loss of liquidity for former shareholders who did not tender
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 25-NSE Filing (Primary) | 0001354457-26-000366 |
| Document: 0001354457-26-000366-index-headers.html | 0001354457-26-000366 |
| Document: 0001354457-26-000366-index.html | 0001354457-26-000366 |
| Document: 0001354457-26-000366.txt | 0001354457-26-000366 |
Track record
6 reports on DAWN
The track record builds as more bullish or bearish reports settle.
Filters
- May 4, 202628w ago 15-12G Neutral 5/10 No price data
- Apr 23, 202629w ago 25-NSE Neutral 9/10 Viewing Entry $21.53 No price data
- Apr 23, 202629w ago 8-K Neutral 9/10 Entry $21.53 No price data
- Apr 17, 202630w ago 10-K/A Neutral 4/10 Entry $21.48 No price data
- Mar 6, 202636w ago Press Release Bullish 9/10 Entry $21.20 to $21.46 ▲ +1.23% +3.27% vs SPY
- Feb 24, 202637w ago 8-K Bullish 8/10 Entry $10.92 to $21.37 ▲ +95.79% +101.02% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers